A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Age-related Macular Degeneration

In brief

From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years. Patients who have been treated with L-DOPA containing medications have a mean age of diagnosis of AMD at 79 years. L-DOPA binds to GPR143 in the retinal pigment epithelium, and releases PEDF, which protects the retina and downregulates VEGF, which is the cause of neovascularization. The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with AMD, and measure the effects on surrogate functional biomarkers of AMD.

Key facts

Study ID
NCT02873351
Run by
Snyder, Robert W., M.D., Ph.D., P.C.
People needed
0
Starts
2019-09-01
Expected to finish
2020-12-01
Last updated by the study team
2019-04-05

Who can join

Age: 50 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.